Help Lines 954-785-1121
 


You are not logged in. Upgrade Here
 <<<Previous Mid Day Report     Next Mid Day Report >>> 
 <<<Previous After Market Report Next After Market Report >>> 
You are not logged in.
This means you CAN ONLY VIEW reports that were published prior to Monday, October 28, 2024.
You MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.

 MIDDAY BREAKOUTS REPORT - THURSDAY, JULY 14TH, 2022
Previous Mid Day Report Next Mid Day Report >>>

DOW 30431.53 -341.26 (-1.11%) | NASDAQ 11160.84 -86.75 (-0.77%) | S&P 500 3765.94 -35.84 (-0.94%)
Time of Screening : 7/14/2022 12:24:23 PM         Report Released : 7/14/2022 12:38:59 PM
Price is: Above 52W High and Less Than 52W High but within 15% of the 52 Week High
Volume Is: At least 45% of 50 Day Average at the time of the screening.
More details about this report...

To View Current Notes and Data on currently Featured Stocks go to the latest
Featured Stocks Page
Symbol/Exchange
Company Name
Industry Group
PRICE CHANGE
(%Change)
Day High Volume
(% DAV)
(50 DAV)
52 Wk Hi
% From Hi
Date
Featured
Price
Featured
Pivot Point
Max Buy
CI - NYSE
Cigna Corp
$264.38 -9.38
-3.42%
$266.82 862,988
45.02% of 50 DAV
50 DAV is 1,917,000
$282.33
-6.36%
7/7/2022 $276.55 PP = $273.68
MB = $287.36
Most Recent Note - 7/14/2022 12:30:05 PM
Y - Gapped down today undercutting prior highs in the $273 area raising concerns while testing support near its 50 DMA line ($261.90), retreating from its all-time high hit this week. More damaging losses would raise greater concerns.
>>> The latest Featured Stock Update with an annotated graph appeared on 7/7/2022. Click here.
View all notes | Alert me of new notes | Company Profile | SEC | News | ChartC A N S L I M

Symbol - Exchange - Industry Group
Company Name
Last Chg Day
High
52 WK Hi % From Hi Volume
% DAV
DAV
ABBV - NYSE - Medical-Ethical Drugs
AbbVie Inc
$150.05 -0.69
-0.46%
$150.58 $175.91 -14.70% 3,911,542
61.79%
6,330,000
Most Recent Note for ABBV - 7/14/2022 12:26:58 PM
Retreated from its all-time high testing its 200 DMA line since last noted with caution in the 4/19/22 mid-day report. Reported earnings +9% on +4% sales revenues for the Mar '22 quarter versus the year ago period. Quarterly and annual earnings history is not a match with the fact-based investment system.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
AZN - NYSE - DRUGS - Drug Manufacturers - Major
Astrazeneca Plc Ads
$64.75 -1.55
-2.34%
$65.02 $71.70 -9.69% 3,241,586
47.21%
6,866,000
Most Recent Note for AZN - 7/14/2022 12:27:34 PM
Consolidating near its 50 DMA line after finding support near its 200 DMA line. Little resistance remains due to overhead supply up to the $71 level. Prior mid-day reports noted - "Prior quarterly and annual earnings history is not a match with the fundamental guidelines of the fact-based investment system."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
ECPG - NASDAQ - FINANCIAL SERVICES - Credit Services
Encore Capital Group Inc
$62.93 -2.90
-4.41%
$65.40 $72.67 -13.40% 268,253
89.12%
301,000
Most Recent Note for ECPG - 7/14/2022 12:31:23 PM
Pulling back today following volume-driven gains. The prior mid-day report cautioned members - "Reported the Mar '22 quarter with strong +115% earnings on +20% sales revenues versus the year ago period. Prior quarterly comparisons were not strong and steady above the +25% minimum earnings guideline (C criteria)."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
ELA - AMEX - Retail/Whlsle-Jewelry
Envela Corporation
$7.30 -0.25
-3.31%
$7.70 $7.74 -5.69% 43,144
53.26%
81,000
Most Recent Note for ELA - 7/14/2022 12:32:39 PM
Perched at its all time high after volume-driven gains. Prior mid-day reports noted - "Reported strong Mar '22 quarterly results versus the year ago period. Prior sales revenues and earnings history has not been a great match with the fact-based investment system's fundamental guidelines."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
GIS - NYSE - FOOD & BEVERAGE - Food - Major Diversified
General Mills Inc
$74.71 -1.72
-2.25%
$75.77 $76.94 -2.90% 2,138,689
54.98%
3,890,000
Most Recent Note for GIS - 7/14/2022 12:33:38 PM
Pulling back today from its all-time high after noted volume-driven gains. Prior mid-day reports cautioned members - "Sub par sales revenues increases and earnings versus year ago quarterly comparisons through May '22 versus the year ago period. Annual earnings growth has been slow and steady for this well-known name in the Food - Packaged industry group. Fundamentals fall short of the C and A criteria of the fact-based investment system."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
GSK - NYSE - Medical-Diversified
Glaxosmithkline Plc Adr
$40.03 -0.89
-2.17%
$40.13 $46.97 -14.78% 3,096,282
51.23%
6,044,000
Most Recent Note for GSK - 7/14/2022 12:34:11 PM
Slumping further below its 200 DMA line again with today's 5th consecutive loss. Recently met resistance near its 50 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
GWW - NYSE - WHOLESALE - Electronics Wholesale
Grainger W W Inc
$451.95 -2.40
-0.53%
$453.09 $529.91 -14.71% 141,906
46.22%
307,000
Most Recent Note for GWW - 7/14/2022 12:35:48 PM
Met resistance at its 200 DMA line ($481) recently and it is testing prior lows in the $440 area with today's 3rd consecutive loss. Noted with caution in the 4/14/22 mid-day report after wedging to new all-time highs with gains lacking great volume conviction. Reported earnings +58% on +18% sales revenues for the quarter ended March 31, 2022 versus the year ago period marking its 3rd consecutive quarterly comparison above the minimum +25% earnings guideline (C criteria). The annual earnings history for this Retail/Wholesale Building Products firm has been up and down which raises concerns with respect to the A criteria of the fact-based investment system's guidelines.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
RBA - NYSE - DIVERSIFIED SERVICES - Business/Management Services
Ritchie Bros Auctioneers
$66.04 +5.70
9.45%
$66.54 $76.18 -13.31% 799,463
158.94%
503,000
Most Recent Note for RBA - 7/14/2022 12:37:25 PM
Rebounding impressively with today's big volume driven gain after a pullback on the prior session tested support near its 50 and 200 DMA lines which closely coincide. Prior mid-day reports cautioned members - "Reported earnings +540% on +19% sales revenues for the Mar '22 quarter versus the year ago period. Prior quarterly and annual earnings (C and A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
USAK - NASDAQ - TRANSPORTATION - Trucking
U S A Truck Inc
$31.20 +0.10
0.32%
$31.29 $31.67 -1.48% 134,488
49.26%
273,000
Most Recent Note for USAK - 7/14/2022 12:38:06 PM
Holding its ground in a tight range near its 52-week high after a gap up on 6/24/22 M&A news. Recent quarterly comparisons through Mar '22 were strong but its prior earnings history is not a match with the fundamental guidelines of the fact-based investment system.
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  
VIVO - NASDAQ - DRUGS - Diagnostic Substances
Meridian Bioscience Inc
$32.63 -0.33
-0.99%
$33.03 $34.38 -5.10% 567,782
74.71%
760,000
Most Recent Note for VIVO - 7/14/2022 12:38:50 PM
Consolidating in a tight range near its 52-week high following volume-driven gains after M&A news. Prior mid-day reports cautioned members - "Quarterly earnings increases through Mar '22 versus the year ago periods have been below the +25% minimum guideline (C criteria). Up and down annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines. On 4/18/08 it was dropped from the Featured Stocks list."
View all notes | Alert me of new notes | Company Profile | SEC  | News | ChartC A N S L I M  

THESE ARE NOT BUY RECOMMENDATIONS!  Comments contained in the body of this report are technical opinions only. The material herein has been obtained from sources believed to be reliable and accurate, however, its accuracy and completeness cannot be guaranteed. We are not an investment advisor, hence it does not endorse or recommend any securities or other investments. Any recommendation contained in this report may not be suitable for all investors and it is not to be deemed an offer or solicitation on our part with respect to the purchase or sale of any securities. All trademarks, service marks and trade names appearing in this report are the property of their respective owners, and are likewise used for identification purposes only.

This report is a service available only to active Paid Premium Members. You may opt-out of receiving report notifications at any time.  Questions or comments may be submitted by writing to FactBasedInvesting.com c/o Premium Member Services 665 S.E. 10 Street, Suite 201 Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.

 We appreciate any feedback members may wish to send via the inquiry form here.

Kenneth J. Gruneisen founded Gruneisen Growth Corp. (2003), which prior to May 11, 2015, operated CANSLIM.net and CANSLIM.com both under license from Data Analysis Inc. / Investor's Business Daily. Kenneth has passed the CAN SLIM® Master's Exam. Gruneisen Growth Corp. now continues over two decades of fact based market analysis via FactBasedInvesting.com.

Copyright © 1996-2024 Gruneisen Growth Corp. All rights reserved. Protected by the copyright laws of the United States and Canada and by international treaties

Privacy Policy | Terms of Use | Contact Us